Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | DHODH | Q02127 | 9/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TACR3 | P29371 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877723 | 0.87 | CYP2C9 (0.59) | PDE10ATSHRDHODHCYP2C9KMT2A | |
| SCHEMBL18075855 | 0.84 | PTGFR (0.65) | DHODHKMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL5960537 | 0.84 | CYP2C9 (0.72) | PDE10ATSHRDHODHCYP2C9KMT2A | |
| SCHEMBL5420651 | 0.80 | DHODH (0.48) | PDE10ATSHRDHODHCYP2C9KMT2A | |
| SCHEMBL1581468 | 0.79 | PDE10A (1.00) | PDE10ATSHRDHODHKMT2A | |
| Hydrochloric Acid SCHEMBL27511204 | 0.78 | PDE10A (0.97) | PDE10ATSHRDHODHKMT2A | |
| SCHEMBL28027247 | 0.77 | ADORA2A (0.52) | PDE10ATSHRCYP2C9KMT2AALDH1A1 | |
| SCHEMBL4879923 | 0.77 | PDE10A (0.72) | PDE10ATSHRDHODHKMT2ATACR3 | |
| SCHEMBL14564768 | 0.76 | CYP2C9 (1.00) | TSHRCYP2C9KMT2AALDH1A1HPGD | |
| SCHEMBL13957825 | 0.74 | PDE10A (1.00) | PDE10ATSHRDHODHKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1812398-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SmithKline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1809606-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SmithKline Beecham Corporation (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20070060593-A1 | 4-Carboxamido quinoline derivatives for use as nk-2 and nk-3 | SMITHKLINE BEECHAM CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060593-A1 | 4-Carboxamido quinoline derivatives for use as nk-2 and nk-3 | SMITHKLINE BEECHAM CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060593-A1 | 4-Carboxamido quinoline derivatives for use as nk-2 and nk-3 | SMITHKLINE BEECHAM CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20060135771-A1 | Quinoline derivatives as nk-2 and nk-3 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-22 | — | — | US | disclosed |
| WO-2006050991-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006050991-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006050992-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| EP-1601360-A2 | QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004066950-A2 | QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060593-A1 | 4-Carboxamido quinoline derivatives for use as nk-2 and nk-3 | KCNK3, KCNQ3, KCNK2 | PDE10A 3652/4885TSHR 2147/4885DHODH 1993/4885 |
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | CNR1, ACKR3, HCAR3 | PDE10A 2915/4885TSHR 94/4885DHODH 3421/4885 |
| US-20060135771-A1 | Quinoline derivatives as nk-2 and nk-3 receptor antagonists | KCNK3, KCNQ3, KCNK2 | PDE10A 3573/4885TSHR 1017/4885DHODH 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.